🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Whitehawk Therapeutics, Inc. WHWK PHARMA

Healthcare · Biotechnology · United States
https://ir.whitehawktx.com
Company Profile ↓
$4.55
+166.08% 1Y
Mkt Cap$259.39M
P/E-3.76
P/B1.71
52W High$5.10
52W Low$1.60
Book Value$2.46
EPS (TTM)$-1.21

Company Overview

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.00.

Recent Developments

  • Dec 2025 Revenue of $7.14M (-72.5% YoY); net profit $-20.60M.
  • Trailing 12 Months Year-on-year growth — revenue -72.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR -15.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-15.87%
1 Year:-72.50%

Stock Price Performance

1 Year:+166.08%
6 Months:+21.33%
3 Months:+9.64%
1 Month:-3.19%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 84% of range
$1.60 $5.10
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)49.65 · Neutral
Price Performance
1M-3.19%
3M+9.64%
6M+21.33%
1Y+166.08%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -15.9% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-3.76
Industry PE
24.83
Forward P/E
-4.61
PEG Ratio
-
Book Value
$2.46
Price to Book
1.71
P/S
inf
EV/EBITDA
-0.57
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-15.87%
Profit 5Y
-
Revenue (YoY)
-72.50%
Earnings (YoY)
-

Profitability & Returns

ROCE
-83.93%
ROE
-44.98%
ROA
-28.70%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.32
EPS (TTM)
$-1.21

Balance Sheet & Liquidity

Debt/Equity
0.00
Quick Ratio
17.16
Current Ratio
17.38
Debt
$0
Total Assets
$127.23M
Current Assets
$125.55M
Working Capital
$134.49M

Ownership

Promoter Holding
12.62%
Chg in Prom Hold
-0.76%
FII / Inst Holding
80.98%
Chg in FII Hold
0.05%

Financial Snapshot

Enterprise Value
$259.39M
Total Revenue (TTM)
$0
EBITDA
$-86.06M
Free Cash Flow
$-43.61M
Operating Cash Flow
$-69.35M
Shares Outstanding
57.01M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 WHWK Whitehawk Therapeutics, Inc. PHARMA 4.55 -3.76 $259.39M 0.00% -83.93% -44.98% -15.87% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ------------1.33M18.82M2.14K-----15.00M231.00K120.00K002.31M3.44M4.25M5.87M6.20M5.96M5.35M6.18M7.21M-7.14M0000
Cost of Revenue -----------------------------------760.00K0000
Gross Profit -----------------------------------6.38M0000
Operating Expenses -----------------------------------21.60M54.75M19.55M24.89M23.52M
Operating Income -3.96K-5.10K-4.33K-4.21M-4.38M-4.75M-3.31M-4.76M-5.58M-4.76M-6.29M-7.48M-6.04M11.20M-8.87M-8.84M-5.98M-4.97M-4.66M-4.11M9.26M-2.66M-4.09M-3.88M-87.31M-13.81M-18.36M-15.04M-16.82M-19.55M-17.85M-19.51M-15.58M-13.41M--15.22M-54.75M-19.55M-24.89M-23.52M
EBITDA ------------------------------------15.16M-52.60M-17.74M-23.25M-23.52M
Interest Expense ----------------------------------00000-
Pretax Income -----------------------------------73.02M-52.62M-17.75M-23.25M-22.19M
Tax Provision -----------------------------------0---0
Net Income -5.82K-7.27K-6.52K-4.19M-4.39M-4.89M-3.52M-5.00M-5.52M-4.65M-6.24M-7.43M-5.99M11.54M--8.49M-5.68M-4.65M--3.32M-5.28M-2.89M-5.48M-1.54M-87.09M-13.86M-18.27M-14.47M-15.22M-17.97M-16.30M-18.29M-14.58M-12.55M-73.02M-52.62M-17.75M-23.25M-22.19M
Diluted EPS ------------------------0.60-9.17-0.66-0.87-0.68-0.57-0.67-0.60-0.68-0.54-0.46-1.83-0.76-0.26-0.34-0.32
R&D Expense ---2.99M2.90M3.48M-2.26M3.17M2.94M-4.03M4.23M4.35M-5.59M2.26M2.84M-1.83M3.55M2.40M3.64M3.04M5.75M6.79M7.73M8.77M10.96M13.31M11.89M13.59M13.09M10.00M-8.79M48.81M14.35M-17.23M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ----------20.16M014.00M-15.22M24.35M25.98M7.14M
Cost of Revenue --------------1.33M2.81M3.02M760.00K
Gross Profit --------------13.88M21.55M22.96M6.38M
Operating Expenses --------------72.84M93.48M87.78M120.78M
Operating Income ---20.51K-23.59K-22.39K-22.82K-23.97K-23.01K-16.63M-21.39M-11.18M-24.44M-2.55M--58.96M-71.93M-64.82M-114.40M
EBITDA ---------------60.12M-65.36M-63.34M-20.52M
Interest Expense --------------230.00K231.00K154.00K0
Pretax Income ---------------60.51M-65.77M-63.69M-20.60M
Tax Provision --------------0000
Net Income -33.62K-20.00K-22.39K-27.18K-27.36K-28.70K-30.80K-31.44K-16.98M-21.40M-10.40M-23.27M-3.48M--60.51M-65.77M-63.69M-20.60M
Diluted EPS ---------------2.69-2.44-2.36-0.33
R&D Expense --------11.37M12.15M17.85M12.82M15.01M19.67M32.66M48.93M51.03M90.96M

Balance Sheet (Annual)

Figures in USD.

Metric Nov 2007Dec 2007Dec 2008Dec 2009Dec 2010Sep 2011Dec 2011Sep 2012Dec 2012Dec 2013Dec 2014Sep 2015Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --------8.11K8.78K5.26K-18.53K2.40M21.03M64.12M39.94M18.82M-184.24M132.42M70.32M150.83M
Current Assets -------------------180.03M124.59M61.29M149.01M
Cash & Equivalents 0--11.14K26.90K6.13K4.12K5.39K4.61K6.28K5.26K6.27K5.14M1.61M20.26M62.61M38.52M4.46M-39.02M62.89M28.67M37.57M
Inventory -------------------1.86M6.43M5.31M0
Receivables -------------------1.86M5.49M5.90M0
Total Liabilities ---------------5.46M3.40M31.26M-25.86M27.23M17.84M14.52M
Current Liabilities ----70.39K-74.80K-103.65K133.03K160.30K-205.01K14.86M3.59M5.46M3.33M30.06M-18.84M26.39M17.07M14.52M
Long Term Debt -----------------------
Total Debt -------------------1.66M1.27M833.00K0
Total Equity 035.02K1.40K-18.60K-40.99K--68.18K--95.54K-124.24K-155.04K--66.55M-86.22M17.44M58.67M-9.09M-12.43M-158.38M105.19M52.48M136.31M
Shares Outstanding -------------------24.44M24.55M24.68M47.15M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -19.24K-22.77K-24.52K-23.32K-16.02K-21.73K-24.52K-18.88M-5.81M-23.85M-12.70M--49.64M-59.66M-59.55M-97.43M
Investing Cash Flow -------41.10K-37.91K-236.95K-19.02K--132.89M83.21M25.20M11.89M
Financing Cash Flow 35.00K025.00K25.00K15.00K35.00K10.00K37.50M48.20M-1.19M-72.62M326.00K130.00K94.38M
Capital Expenditure -------113.30K-8.90K-37.91K-236.95K-19.02K--444.00K-3.97M-1.65M-552.00K
Free Cash Flow -------137.81K-18.89M-5.85M-24.09M-12.72M--50.08M-63.63M-61.20M-97.98M
Net Change in Cash -------------109.91M23.87M-34.22M8.83M
Dividends Paid -----------4.41M0---

Ratios (Annual)

Figures in %.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------------91.2%88.5%88.4%89.4%
Operating Margin % -----------55.5%--18.2%--387.5%-295.4%-249.5%-1,601.1%
Net Margin % -----------51.6%--24.8%--397.7%-270.0%-245.1%-288.3%
ROE % -2,401.6%107.5%54.6%39.9%28.6%23.1%19.9%0.0%19.7%-122.7%-17.7%255.9%28.0%--38.2%-62.5%-121.4%-15.1%
ROCE % ----23.4%18.4%15.5%12.3%133.5%-122.7%-19.1%-66.8%22.7%--35.6%-67.8%-121.7%-83.9%

Shareholding Pattern

Insiders
12.62%
Institutions
80.98%
Public Float
92.68%

Top Institutional Holders

#Holder% HeldSharesValue
1 Yu Fan 8.53% 4.86M $20.42M
2 Acuta Capital Partners LLC 8.22% 4.69M $19.68M
3 QVT Financial LP 8.10% 4.62M $19.39M
4 Montanova Capital LLC 7.54% 4.30M $18.06M
5 Orbimed Advisors LLC. 6.90% 3.93M $16.52M
6 Avoro Capital Advisors LLC 5.00% 2.85M $11.97M
7 Siren, L.L.C. 4.10% 2.34M $9.82M
8 Kvp Capital Advisors, LP 3.80% 2.17M $9.10M
9 Blackrock Inc. 3.37% 1.92M $8.08M
10 Vanguard Capital Management LLC 2.44% 1.39M $5.83M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for WHWK

Yahoo Finance Fri, 28 Aug 2026

What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?

Does Whitehawk Therapeutics, Inc. (WHWK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Yahoo Finance Wed, 26 Aug 2026

Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know

The mean of analysts' price targets for Whitehawk Therapeutics, Inc. (WHWK) points to a 47.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earning…

Yahoo Finance ue, 21 Jul 2026

Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics

Collaboration will evaluate Akari's PH1 payload technology in combination with Whitehawk's TOP1i payload to generate potential future development opportunitiesTAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc…

Yahoo Finance ue, 07 Jul 2026

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

BOSTON & MORRISTOWN, N.J., July 07, 2026--Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. ("Whitehawk," Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Bioc…

Yahoo Finance Wed, 10 Jun 2026

Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), featuring a year-to-date gain of 71.49% and upside potential of 68.70%, secures a spot on our list of hot biotech stocks under $5 to buy. A busy period of pipeline and platform news has kept the c…

Yahoo Finance Sat, 30 May 2026

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today a…

WHWK — Frequently Asked Questions

What is the current share price of Whitehawk Therapeutics, Inc. (WHWK)?

As of 2026-09-19 21:16 PDT, Whitehawk Therapeutics, Inc. (WHWK) trades at $4.55 on NasdaqCM. Its 52-week range is $1.60 to $5.10.

What is the market capitalisation of WHWK?

Whitehawk Therapeutics, Inc. (WHWK) has a market capitalisation of $259.39M on NasdaqCM.

What is the P/E ratio of WHWK?

WHWK trades at a trailing price-to-earnings (P/E) ratio of -3.76. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.71.

What is the return on equity (ROE) of WHWK?

WHWK has a return on equity (ROE) of -44.98%. Its return on capital employed (ROCE) is -83.93%.

Is WHWK a good stock to buy?

This page provides a data-driven analysis of Whitehawk Therapeutics, Inc. (WHWK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space